You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 Google Custom Search

Apricitabine

What is apricitabine?

Apricitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI).

Avexa Announces End to Development of Experimental NNRTI Apricitabine
5-11-2010

Newer Anti-HIV Drugs and How to Use Them: Part I

6-23-2009

Safety Monitoring Board Says Phase 3 Trial of Experimental NRTI Apricitabine Can Go Forward Using Lower Dose
6-16-2009


New NRTI Apricitabine Demonstrates Good Safety in Early Clinical Trial
8-22-2008

Apricitabine Effective Against Drug-resistant HIV
8-01-2008

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


FDA-approved HIV
and AIDS Treatments
Protease Inhibitors PIs
non Nucleoside Reverse
  
Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide
  
Reverse Transcriptase Inhibitors NRTIs
Fixed-dose Combinations
Entry / Fusion Inhibitors EIs
Integrase Inhibitors

Experimental Treatments

HIV and AIDS
Articles by Topic
Adverse Events
Opportunistic Infections
Metabolic Complications
Lipodystrophy - Fat Redistribution
Treatment Guidelines
Women/Children